CD4 CTL: Living up to the challenge

Seminars in Immunology

Volumn 25, Issue 4, 2013, Pages 273-281

  Cheroutre, Hilde ^a   Husain, Mohammad Mushtaq ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Autoimmunity; CD4 T helper cells; CD8 cytotoxic T lymphocyte; Chronic viral infection; Functional reprogramming; Intestine; Lineage commitment; Plasticity; Protective immunity; Runx3; ThPOK; Tumor

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ALPHA ALPHA ANTIGEN; CD8 ALPHA BETA ANTIGEN; CD8 ANTIGEN; GRANZYME B; HERMES ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 22; INTERLEUKIN 23 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NOTCH1 RECEPTOR; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX3; TRANSCRIPTION FACTOR T BET; TRANSCRIPTION FACTOR THPOK; UNCLASSIFIED DRUG;

ALPHA CHAIN; ANKYLOSING SPONDYLITIS; ANTIGEN EXPRESSION; AUTOIMMUNE DISEASE; BETA CHAIN; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FATE; CELL LINEAGE; CELL POLARITY; CELLULAR DISTRIBUTION; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; GENE EXPRESSION; GENE REPRESSION; INFECTION CONTROL; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; NEGATIVE FEEDBACK; NONHUMAN; NUCLEAR REPROGRAMMING; PRE T LYMPHOCYTE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH17 CELL; TH2 CELL; THYMOCYTE; THYMUS; TRANSCRIPTION REGULATION; UPREGULATION; VIRAL CLEARANCE; VIRUS IMMUNITY; VIRUS INFECTION;

AUTOIMMUNITY; CD4 T HELPER CELLS; CD8ΑΒ CYTOTOXIC T LYMPHOCYTE; CHRONIC VIRAL INFECTION; FUNCTIONAL REPROGRAMMING; INTESTINE; LINEAGE COMMITMENT; PLASTICITY; PROTECTIVE IMMUNITY; RUNX3; THPOK; TUMOR;

ANIMALS; AUTOIMMUNE DISEASES; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINEAGE; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; LYMPHOCYTE ACTIVATION; LYMPHOID TISSUE; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, HELPER-INDUCER; THYMUS GLAND; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 84888868711     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2013.10.022     Document Type: Review

References (113)

1. Aliahmad P., Kadavallore A., de la Torre B., Kappes D., Kaye J. TOX is required for development of the CD4 T cell lineage gene program. J Immunol 2011, 187:5931-5940.
2. He X., He X., Dave V.P., Zhang Y., Hua X., Nicolas E., et al. The zinc finger transcription factor Th-POK regulates CD4 versus CD8 T-cell lineage commitment. Nature 2005, 433:826-833.
3. Hernández-Hoyos G., Anderson M.K., Wang C., Rothenberg E.V., Alberola-Ila J. GATA-3 expression is controlled by TCR signals and regulates CD4/CD8 differentiation. Immunity 2003, 19:83-94.
4. Mucida D., Husain M.M., Muroi S., van Wijk F., Shinnakasu R., Naoe Y., et al. Transcriptional reprogramming of mature CD4+ helper T cells generates distinct MHC class II-restricted cytotoxic T lymphocytes. Nat Immunol 2013, 14:281-289.
5. Pai S.Y., Truitt M.L., Ting C.N., Leiden J.M., Glimcher L.H., Ho I.C. Critical roles for transcription factor GATA-3 in thymocyte development. Immunity 2003, 19:863-875.
6. Sun G., Liu X., Mercado P., Jenkinson S.R., Kypriotou M., Feigenbaum L., et al. The zinc finger protein cKrox directs CD4 lineage differentiation during intrathymic T cell-positive selection. Nat Immunol 2005, 6:373-381.
7. Wang L., Wildt K.F., Castro E., Xiong Y., Feigenbaum L., Tessarollo L., et al. The zinc finger transcription factor Zbtb7b represses CD8-lineage gene expression in peripheral CD4+ T cells. Immunity 2008, 29:876-887.
8. Taniuchi I., Osato M., Egawa T., Sunshine M.J., Bae S.C., Komori T., et al. Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell 2002, 111:621-633.
9. Woolf E., Xiao C., Fainaru O., Lotem J., Rosen D., Negreanu V., et al. Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis. Proc Natl Acad Sci USA 2003, 100:7731-7736.
10. van de Berg P.J., van Leeuwen E.M., ten Berge I.J., van Lier R. Cytotoxic human CD4+ T cells. Curr Opin Immunol 2008, 20:339-343.
11. Brown D.M. Cytolytic CD4 cells: direct mediators in infectious disease and malignancy. Cell Immunol 2010, 262:89-95.
12. Krensky A.M., Reiss C.S., Mier J.W., Strominger J.L., Burakoff S.J. Long-term human cytolytic T-cell lines allospecific for HLA-DR6 antigen are OKT4. Proc Natl Acad Sci USA 1982, 79:2365-2369.
13. Lukacher A.E., Morrison L.A., Braciale V.L., Malissen B., Braciale T.J. Expression of specific cytolytic activity by H-2I region-restricted, influenza virus-specific T lymphocyte clones. J Exp Med 1985, 162:171-187.
14. McCarthy SA,S.A. Recognition of MHC class I allodeterminants regulates the generation of MHC class II-specific CTL. J Immunol 1986, 137:3087-3092.
15. Man S., Lechler R.I., Batchelor J.R., Sharrock C.E. Individual variation in the frequency of HLA class II-specific cytotoxic T lymphocyte precursors. Eur J Immunol 1990, 20:847.
16. Suni M.A., Ghanekar S.A., Houck D.W., Maecker H.T., Wormsley S.B., Picker L.J., et al. CD4 CD8dim T lymphocytes exhibit enhanced cytokine expression, proliferation and cytotoxic activity in response to HCMV and HIV-1 antigens. Eur J Immunol 2001, 31:2512.
17. Fleischer B. Acquisition of specific cytotoxic activity by human T4+ T lymphocytes in culture. Nature 1984, 308:365-367.
18. Williams N.S., Engelhard V.H. Identification of a population of CD4+ CTL that utilizes a perforin, rather than a Fas ligand-dependent cytotoxic mechanism. J Immunol 1996, 156:153-159.
19. Reis B.S., Rogoz A., Costa-Pinto F.A., Taniuchi I., Mucida D. Mutual expression of the transcription factors Runx3 and ThPOK regulates intestinal CD4+ T cell immunity. Nat Immunol 2013, 14:271-280.
20. Naito T., Tanaka H., Naoe Y., Taniuchi I. Transcriptional control of T-cell development. Int Immunol 2011, 23:661-668.
21. Gangadharan D., Lambolez F., Attinger A., Wang-Zhu Y., Sullivan B.A., Cheroutre H. Identification of pre- and postselection TCRalphabeta+ intraepithelial lymphocyte precursors in the thymus. Immunity 2006, 25:631-641.
22. Zhu J., Min B., Hu-Li J., Watson C.J., Grinberg A., Wang Q., et al. Conditional deletion of Gata3 shows its essential function in T(H)1-T(H)2 responses. Nat Immunol 2004, 5:1157-1165.
23. Ho I.C., Tai T.S., Pai S.Y. GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation. Nat Rev Immunol 2009, 9:125-135.
24. Hendriks R.W., Nawijn M.C., Engel J.D., van Doorninck H., Grosveld F., Karis A. Expression of the transcription factor GATA-3 is required for the development of the earliest T cell progenitors and correlates with stages of cellular proliferation in the thymus. Eur J Immunol 1999, 29:1912-1918.
25. Wang L., Wildt K.F., Zhu J., Zhang X., Feigenbaum L., Tessarollo L., et al. Distinct functions for the transcription factors GATA-3 and ThPOK during intrathymic differentiation of CD4+ T cells. Nat Immunol 2008, 9:1122-1130.
26. Egawa T., Littman D.R. ThPOK acts late in specification of the helper T cell lineage and suppresses Runx-mediated commitment to the cytotoxic T cell lineage. Nat Immunol 2008, 9:1131-1139.
27. Setoguchi R., Tachibana M., Naoe Y., Muroi S., Akiyama K., Tezuka C., et al. Repression of the transcription factor Th-POK by Runx complexes in cytotoxic T cell development. Science 2008, 319:822-825.
28. Kappes D.J., He X., He X. Role of the transcription factor Th-POK in CD4:CD8 lineage commitment. Immunol Rev 2006, 209:237-252.
29. Cruz-Guilloty F., Pipkin M.E., Djuretic I.M., Levanon D., Lotem J., Lichtenheld M.G., et al. Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. J Exp Med 2009, 206:51-59.
30. Egawa T., Tillman R.E., Naoe Y., Taniuchi I., Littman D.R. The role of the Runx transcription factors in thymocyte differentiation and in homeostasis of naive T cells. J Exp Med 2007, 204:1945-1957.
31. Sato T., Ohno S., Hayashi T., Sato C., Kohu K., Satake M., et al. Dual functions of Runx proteins for reactivating CD8 and silencing CD4 at the commitment process into CD8 thymocytes. Immunity 2005, 22:317-328.
32. Collins A., Littman D.R., Taniuchi I. RUNX proteins in transcription factor networks that regulate T-cell lineage choice. Nat Rev Immunol 2009, 9:106-115.
33. Liu X., Taylor B.J., Sun G., Bosselut R. Analyzing expression of perforin, Runx3, and Thpok genes during positive selection reveals activation of CD8-differentiation programs by MHC II-signaled thymocytes. J Immunol 2005, 175:4465-4474.
34. Grueter B., Petter M., Egawa T., Laule-Kilian K., Aldrian C.J., Wuerch A., et al. Runx3 regulates integrin alpha E/CD103 and CD4 expression during development of CD4-/CD8+ T cells. J Immunol 2005, 175:1694-1705.
35. Kohu K., Sato T., Ohno S., Hayashi K., Uchino R., Abe N., et al. Overexpression of the Runx3 transcription factor increases the proportion of mature thymocytes of the CD8 singlepositive lineage. J Immunol 2005, 174:2627-2636.
36. Bilic I., Ellmeier W. The role of BTB domain-containing zinc finger proteins in T cell development and function. Immunol Lett 2007, 108:1-9.
37. Bilic I., Koesters C., Unger B., Sekimata M., Hertweck A., Maschek R., et al. Negative regulation of CD8 expression via Cd8 enhancermediated recruitment of the zinc finger protein MAZR. Nat Immunol 2006, 7:392-400.
38. Laky K., Fowlkes B.J. Notch signaling in CD4 and CD8 T cell development. Curr Opin Immunol 2008, 20:197-202.
39. Laky K., Fowlkes B.J. Presenilins regulate alphabeta T cell development by modulating TCR signaling. J Exp Med 2007, 204:2115-2129.
40. Jones M.E., Zhuang Y. Acquisition of a functional T cell receptor during T lymphocyte development is enforced by HEB and E2A transcription factors. Immunity 2007, 27:860-870.
41. Jimi E., Strickland I., Voll R.E., Long M., Ghosh S. Differential role of the transcription factor NF-κB in selection and survival of CD4+ and CD8+ thymocytes. Immunity 2008, 29:523-537.
42. Djuretic I.M., Levanon D., Negreanu V., Groner Y., Rao A., Ansel K.M. Transcription factors T-bet and Runx3 cooperate to activate Ifng and silence Il4 in T helper type 1 cells. Nat Immunol 2007, 8:145-153.
43. Naoe Y., Setoguchi R., Akiyama K., Muroi S., Kuroda M., Hatam F., et al. Repression of interleukin-4 in T helper type 1 cells by Runx/Cbfβ binding to the Il4 silencer. J Exp Med 2007, 204:1749-1755.
44. Jenkinson S.R., Intlekofer A.M., Sun G., Feigenbaum L., Reiner S.L., Bosselut R. Expression of the transcription factor cKrox in peripheral CD8 T cells reveals substantial postthymic plasticity in CD4-CD8 lineage differentiation. J Exp Med 2007, 204:267-272.
45. Ouyang W., Löhning M., Gao Z., Assenmacher M., Ranganath S., Radbruch A., et al. Stat6-independent GATA-3 autoactivation directs IL-4-independent Th2 development and commitment. Immunity 2000, 12:27-37.
46. Pai S.Y., Truitt M.L., Ho I.C. GATA-3 deficiency abrogates the development and maintenance of T helper type 2 cells. Proc Natl Acad Sci USA 2004, 101:1993-1998.
47. Wang Y., Su M.A., Wan Y.Y. An essential role of the transcription factor GATA-3 for the function of regulatory T cells. Immunity 2011, 35:337-348.
48. Wohlfert E.A., Grainger J.R., Bouladoux N., Konkel J.E., Oldenhove G., Ribeiro C.H., et al. GATA3 controls Foxp3+ regulatory T cell fate during inflammation in mice. J Clin Invest 2011, 121:4503-4515.
49. van Hamburg J.P., de Bruijn M.J., Ribeiro de Almeida C., van Zwam M., van Meurs M., de Haas E., et al. Enforced expression of GATA3 allows differentiation of IL-17-producing cells, but constrains Th17-mediated pathology. Eur J Immunol 2008, 38:2573-2586.
50. Kanhere A., Hertweck A., Bhatia U., Gökmen M.R., Perucha E., Jackson I., et al. T-bet and GATA3 orchestrate Th1 and Th2 differentiation through lineage-specific targeting of distal regulatory elements. Nat Commun 2012, 3:1268.
51. Pearce E.L., Mullen A.C., Martins G.A., Krawczyk C.M., Hutchins A.S., Zediak V.P., et al. Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science 2003, 302:1041-1043.
52. Intlekofer A.M., Banerjee A., Takemoto N., Gordon S.M., Dejong C.S., Shin H., et al. Anomalous type 17 response to viral infection by CD8+ T cells lacking T-bet and eomesodermin. Science 2008, 321:408-411.
53. Li Y., Tsun A., Gao Z., Han Z., Gao Y., Li Z., et al. 60-kDa Tat-interactive protein (TIP60) positively regulates Th-inducing POK (ThPOK)-mediated repression of eomesodermin in human CD4+ T cells. J Biol Chem 2013, 288(22):15537-15546.
54. Carpenter A.C., Grainger J.R., Xiong Y., Kanno Y., Chu H.H., Wang L., et al. The transcription factors Thpok and LRF are necessary and partly redundant for T helper cell differentiation. Immunity 2012, 37:622-633.
55. Casazza J.P., Betts M.R., Price D.A., Precopio M.L., Ruff L.E., Brenchley J.M., et al. Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J Exp Med 2006, 203:2865-2877.
56. Haigh T.A., Lin X., Jia H., Hui E.P., Chan A.T., Rickinson A.B., et al. EBV latent membrane proteins (LMPs) 1 and 2 as immunotherapeutic targets: LMP-specific CD4+ cytotoxic T cell recognition of EBV-transformed B cell lines. J Immunol 2008, 180:1643-1654.
57. Appay V., Zaunders J.J., Papagno L., Sutton J., Jaramillo A., Waters A., et al. Characterization of CD4+ CTLs ex vivo. J Immunol 2002, 168:5954-5958.
58. Marshall N.B., Swain S.L. Cytotoxic CD4 T cells in antiviral immunity. J Biomed Biotechnol 2011, 2011. 954602.
59. Fu J., Zhang Z., Zhou L., Qi Z., Xing S., Lv J., et al. Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. Hepatology 2013, 58:139-149.
60. Martorelli D., Muraro E., Merlo A., Turrini R., Rosato A., Dolcetti R. Role of CD4+ cytotoxic T lymphocytes in the control of viral diseases and cancer. Int Rev Immunol 2010, 29:371-402.
61. Broux B., Pannemans K., Zhang X., Markovic-Plese S., Broekmans T., Eijnde B.O., et al. CX(3)CR1 drives cytotoxic CD4(+)CD28(-) T cells into the brain of multiple sclerosis patients. J Autoimmun 2012, 38(1):10-19.
62. Pawlik A., Ostanek L., Brzosko I., Brzosko M., Masiuk M., Machalinski B., et al. The expansion of CD4+CD28- T cells in patients with rheumatoid arthritis. Arthritis Res Ther 2003, 5:R210-R213.
63. van Leeuwen E.M., Remmerswaal E.B., Vossen M.T., Rowshani A.T., Wertheim-van Dillen P.M., van Lier R.A., et al. Emergence of a CD4+CD28- granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. J Immunol 2004, 173:1834-1841.
64. Kennedy J., Vicari A.P., Saylor V., Zurawski S.M., Copeland N.G., Gilbert D.J., et al. A molecular analysis of NKT cells: identification of a class-I restricted T cell-associated molecule (CRTAM). J Leuk Biol 2000, 67:725-734.
65. Boles K.S., Barchet W., Diacovo T., Cella M., Colonna M. The tumor suppressor TSLC1/NECL-2 triggers NK-cell and CD8+ T-cell responses through the cell-surface receptor CRTAM. Blood 2005, 106:779-786.
66. Boles K.S., Stepp S.E., Bennett M., Kumar V., Mathew P.A. 2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes. Immunol Rev 2001, 181:234-249.
67. Sakaguchi S., Hombauer M., Bilic I., Naoe Y., Schebesta A., Taniuchi I., et al. The zinc-finger protein MAZR is part of the transcription factor network that controls the CD4 versus CD8 lineage fate of double-positive thymocytes. Nat Immunol 2010, 11(5):442-448.
68. Jacobson S., Richert J.R., Biddison W.E., Satinsky A., Hartzman R.J., McFarland H.F. Measles virus-specificT4+ human cytotoxic T cell clones are restricted by class II HLA antigens. J Immunol 1984, 133:754-757.
69. DePaolo R.W., Abadie V., Tang F., Fehlner-Peach H., Hall J.A., Wang W., et al. Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. Nature 2011, 471:220-224.
70. Mention J.J., Ben Ahmed M., Bègue B., Barbe U., Verkarre V., Asnafi V., et al. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterol 2003, 125:730-745.
71. Ebert E.C. Interleukin 15 is a potent stimulant of intraepithelial lymphocytes. Gastroenterol 1998, 115:1439-1445.
72. Ye W., Young J.D., Liu C.C. Interleukin-15 induces the expression of mRNAs of cytolytic mediators and augments cytotoxic activities in primary murine lymphocytes. Cell Immunol 1996, 174:54-62.
73. Abadie V., Discepolo V., Jabri B. Intraepithelial lymphocytes in celiac disease immunopathology. Semin Immunopathol 2012, 34:551-566.
74. Haywood A.M. Patterns of persistent viral infections. N Engl J Med 1986, 315:939-948.
75. Hirsch M.S. Cytomegalovirus and its role in the pathogenesis of acquired immunodeficiency syndrome. Transplant Proc 1991, 23:118-121.
76. Kang S.S., McGavern D.B. Lymphocytic choriomeningitis infection of the central nervous system. Front Biosci 2008, 13:4529-4543.
77. Jellison E.R., Kim S.-K., Welsh R.M. Cutting edge: MHC class II-restricted killing in vivo during viral infection. J Immunol 2005, 174:614-618.
78. Arens R., Wang P., Sidney J., Loewendorf A., Sette A., Schoenberger S.P., et al. Cutting edge: murine cytomegalovirus induces a polyfunctional CD4 T cell response. J Immunol 2008, 180:6472-6476.
79. Jonjić S., Pavić I., Lucin P., Rukavina D., Koszinowski U.H. Efficacious control of cytomegalovirus infection after long-term depletion of CD8+ T lymphocytes. J Virol 1990, 64:5457-5464.
80. Rentenaar R.J., Gamadia L.E., van DerHoek N., van Diepen F.N., Boom R., Weel J.F., et al. Development of virus-specific CD4(+) T cells during primary cytomegalovirus infection. J Clin Invest 2000, 105:541-548.
81. van Leeuwen E.M., Remmerswaal E.B., Heemskerk M.H., ten Berge I.J., van Lier R.A. Strong selection of virus-specific cytotoxic CD4+ T-cell clones during primary human cytomegalovirus infection. Blood 2006, 108:3121-3127.
82. Crompton L., Khan N., Khanna R., Nayak L., Moss P.A. CD4+ T cells specific for glycoprotein B from cytomegalovirus exhibit extreme conservation of T-cell receptor usage between different individuals. Blood 2008, 111:2053-2061.
83. Elkington R., Shoukry N.H., Walker S., Crough T., Fazou C., Kaur A., et al. Cross-reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes specific for glycoprotein B and H. Eur J Immunol 2004, 34:3216-3226.
84. Hegde N.R., Dunn C., Lewinsohn D.M., Jarvis M.A., Nelson J.A., Johnson D.C. Endogenous human cytomegalovirus gB is presented efficiently by MHC class II molecules to CD4+ CTL. J Exp Med 2005, 202:1109-1119.
85. Zheng C.F., Ma L.L., Jones G.J., Gill M.J., Krensky A.M., Kubes P., et al. Cytotoxic CD4+ T cells use granulysin to kill Cryptococcus neoformans, and activation of this pathway is defective in HIV patients. Blood 2007, 109:2049-2057.
86. Sáez-Borderías A., Gumá M., Angulo A., Bellosillo B., Pende D., López-Botet M. Expression and function of NKG2D in CD4+ T cells specific for human cytomegalovirus. Eur J Immunol 2006, 36:3198-3206.
87. Zhou W., Sharma M., Martinez J., Srivastava T., Diamond D.J., Knowles W., et al. Functional characterization of BK virus-specific CD4+ T cells with cytotoxic potential in seropositiveadults. Viral Immunol 2007, 20:379-388.
88. Milikan J.C., Kinchington P.R., Baarsma G.S., Kuijpers R.W., Osterhaus A.D., Verjans G.M. Identification of viral antigens recognized by ocular infiltrating T cells from patients with varicella zoster virus-induced uveitis. Invest Ophthalmol Vis Sci 2007, 48:3689-3697.
89. Aslan N., Yurdaydin C., Wiegand J., Greten T., Ciner A., Meyer M.F., et al. Cytotoxic CD4 T cells in viral hepatitis. J Viral Hepat 2006, 13:505-514.
90. Silva C.L., Lowrie D.B. Identification and characterization of murine cytotoxic T cells that kill Mycobacterium tuberculosis. Infect Immun 2000, 68:3269-3274.
91. Landmeier S., Altvater B., Pscherer S., Eing B.R., Kuehn J., Rooney C.M., et al. Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function. Cancer Res 2007, 67:8335-8343.
92. Ohminami H., Yasukawa M., Kaneko S., Yakushijin Y., Abe Y., Kasahara Y., et al. Fas-independent and nonapoptotic cytotoxicity mediated by a human CD4(+) T-cell clone directed against an acute myelogenous leukemia-associated DEK-CAN fusion peptide. Blood 1999, 93:925-935.
93. Hanley P.J., Cruz C.R., Savoldo B., Leen A.M., Stanojevic M., Khalil M., et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009, 114:1958-1967.
94. McKinstry K.K., Strutt T.M., Kuang Y., Brown D.M., Sell S., Dutton R.W., et al. Memory CD4+ T cells protect against influenza through multiple synergizing mechanisms. J Clin Invest 2012, 122:2847-2856.
95. Hegde N.R., Johnson D.C. Human cytomegalovirus US2 causes similar effects on both major histocompatibility complex class I and II proteins in epithelial and glial cells. J Virol 2003, 77:9287-9294.
96. von Herrath M., Holz A. Pathological changes in the islet milieu precede infiltration of islets and destruction of beta-cells by autoreactive lymphocytes in a transgenic model of virus-induced IDDM. J Autoimmun 1997, 10:231-238.
97. Debbabi H., Ghosh S., Kamath A.B., Alt J., Demello D.E., Dunsmore S., et al. Primary type II alveolar epithelial cells present microbial antigens to antigen-specific CD4+ T cells. Am J Physiol Lung Cell Mol Physiol 2005, 289:L274-L279.
98. Gao J., De B.P., Banerjee A.K. Human parainfluenza virus type 3 up-regulates major histocompatibility complex class I and II expression on respiratory epithelial cells: involvement of a STAT1- and CIITA-independent pathway. J Virol 1999, 72:1411-1418.
99. Ibrahim L., Dominguez M., Yacoub M. Primary human adult lung epithelial cells in vitro: response to interferon-gamma and cytomegalovirus. Immunol 1993, 79:119-124.
100. Bottazzo G.F., Dean B.M., McNally J.M., MacKay E.H., Swift P.G., Gamble D.R. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 1985, 313:353-360.
101. Foulis A.K., Farquharson M.A. Aberrant expression of HLA-DR antigens by insulin-containing beta-cells in recent-onset type I diabetes mellitus. Diabetes 1986, 35:1215-1224.
102. Seewaldt S., Thomas H.E., Ejrnaes M., Christen U., Wolfe T., Rodrigo E., et al. Virus-induced autoimmune diabetes: most beta-cells die through inflammatory cytokines and not perforin from autoreactive (anti-viral) cytotoxic T-lymphocytes. Diabetes 2000, 49:1801-1809.
103. Robertson K.A., Usherwood E.J., Nash A.A. Regression of a murine gammaherpesvirus 68-positive b-cell lymphoma mediated by CD4 T lymphocytes. J Virol 2001, 75:3480-3482.
104. Sparks-Thissen R.L., Braaten D.C., Kreher S., Speck S.H., Virgin H.W. An optimized CD4 T-cell response can control productive and latent gammaherpesvirus infection. J Virol 2004, 78:6827-6835.
105. Nikiforow S., Bottomly K., Miller G. CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation. J Virol 2001, 75:3740-3752.
106. Heller K.N., Gurer C., Münz C. Virus-specific CD4+ T cells: ready for direct attack. J Exp Med 2006, 203:805-808.
107. Paludan C., Bickham K., Nikiforow S., Tsang M.L., Goodman K., Hanekom W.A., et al. Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J Immunol 2002, 169:1593-1603.
108. Bollard C.M., Gottschalk S., Leen A.M., Weiss H., Straathof K.C., Carrum G., et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007, 110:2838-2845.
109. Thewissen M., Somers V., Hellings N., Fraussen J., Damoiseaux J., Stinissen P. CD4+CD28null T cells in autoimmune disease: pathogenic features and decreased susceptibility to immunoregulation. J Immunol 2007, 179:6514-6523.
110. Kobayashi T., Okamoto S., Iwakami Y., Nakazawa A., Hisamatsu T., Chinen H., et al. Exclusive increase of CX3CR1+CD28-CD4+ T cells in inflammatory bowel disease and their recruitment as intraepithelial lymphocytes. Inflamm Bowel Dis 2007, 13:837-846.
111. Rizzello V., Liuzzo G., Brugaletta S., Rebuzzi A., Biasucci L.M., Crea F. Modulation of CD4(+)CD28null T lymphocytes by tumor necrosis factor-alpha blockade in patients with unstable angina. Circulation 2006, 113:2272-2277.
112. Raffeiner B., Dejaco C., Duftner C., Kullich W., Goldberger C., Vega S.C., et al. Between adaptive and innate immunity: TLR4-mediated perforin production by CD28null T-helper cells in ankylosing spondylitis. Arthritis Res Ther 2005, 7:R1412-R1420.
113. Gerli R., Schillaci G., Giordano A., Bocci E.B., Bistoni O., Vaudo G., et al. CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 2004, 109:2744-2748.